{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:35:29Z","timestamp":1771511729763,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.2515\/therapie\/2011012","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T11:11:49Z","timestamp":1307099509000},"page":"123-130","source":"Crossref","is-referenced-by-count":3,"title":["Prescription de l\u2019aripiprazole chez l\u2019enfant et l\u2019adolescent"],"prefix":"10.1016","volume":"66","author":[{"given":"Claire","family":"Chevreuil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Guillemot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011012_bb0005","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","article-title":"Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder","volume":"64","author":"Swainston Harrison","year":"2004","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2011012_bb0010","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0149-2918(04)90066-5","article-title":"Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability","volume":"26","author":"DeLeon","year":"2004","journal-title":"Clin Ther"},{"key":"10.2515\/therapie\/2011012_bb0015","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"McGavin","year":"2002","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2011012_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.encep.2008.12.001","article-title":"A new pharmacological strategy for schizophrenia: the partial agonists of D2 dopaminergic receptors. The principle characteristics of aripiprazole","volume":"35","author":"Costentin","year":"2009","journal-title":"Encephale"},{"key":"10.2515\/therapie\/2011012_bb0025","series-title":"R\u00e9sum\u00e9 des Caract\u00e9ristiques du Produit aripiprazole","year":"2010"},{"key":"10.2515\/therapie\/2011012_bb0030","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2165\/11310820-000000000-00000","article-title":"Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder","volume":"23","author":"Mace","year":"2009","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2011012_bb0035","first-page":"250","article-title":"Focus on aripiprazole: a review of its use in child and adolescent psychiatry","volume":"18","author":"Greenaway","year":"2009","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/030079906X158075","article-title":"Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004","volume":"23","author":"Aparasu","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2011012_bb0045","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ps.2008.59.10.1162","article-title":"Changing trends in pediatric antipsychotic use in Florida\u2019s Medicaid program","volume":"59","author":"Constantine","year":"2008","journal-title":"Psychiatr Serv"},{"key":"10.2515\/therapie\/2011012_bb0050","first-page":"188","article-title":"Prescription of olanzapine in children and adolescent psychiatric patients","volume":"33","author":"Fremaux","year":"2007","journal-title":"Encephale"},{"key":"10.2515\/therapie\/2011012_bb0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2515\/therapie:2008059","article-title":"Risperidone use in child and adolescent psychiatric patients","volume":"63","author":"Chevreuil","year":"2008","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2011012_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2515\/therapie\/2010001","article-title":"Pharmacologic treatment of insomnia in children and adolescent pyschiatric patients","volume":"65","author":"Chevreuil","year":"2010","journal-title":"Therapie"},{"issue":"Suppl","key":"10.2515\/therapie\/2011012_bb0065","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2152\/jmi.52.284","article-title":"Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist","volume":"52","author":"Hirose","year":"2005","journal-title":"J Med Invest"},{"key":"10.2515\/therapie\/2011012_bb0070","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.2515\/therapie\/2011012_bb0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","article-title":"Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers","volume":"44","author":"Mallikaarjun","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011012_bb0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","article-title":"Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study","volume":"28","author":"Findling","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0085","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/FTD.0b013e3181633429","article-title":"Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia","volume":"30","author":"Bachmann","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011012_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/15622970701361255","article-title":"Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects","volume":"9","author":"Kirschbaum","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1055\/s-2007-977715","article-title":"Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service","volume":"40","author":"Castberg","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.2515\/therapie\/2011012_bb0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/FTD.0b013e3181956726","article-title":"Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole","volume":"31","author":"Waade","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.2515\/therapie\/2011012_bb0105","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-007-0373-6","article-title":"Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole","volume":"63","author":"Hendset","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011012_bb0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-009-1538-z","article-title":"HTR2A A-1438G\/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients","volume":"205","author":"Chen","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.2515\/therapie\/2011012_bb0115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/JCP.0b013e318172757f","article-title":"Aripiprazole-induced parkinsonism and its association with dopamine and serotonin receptor polymorphisms","volume":"28","author":"Lopez-Torres","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0125","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740330902835493","article-title":"A review of the safety and tolerability of aripiprazole","volume":"8","author":"Pae","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.2515\/therapie\/2011012_bb0130","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychoticinduced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly","year":"2009","journal-title":"Schizophr Res"},{"key":"10.2515\/therapie\/2011012_bb0140","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4088\/JCP.v69n0702","article-title":"A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine","volume":"69","author":"Newcomer","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0145","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2011012_bb0150","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/01.chi.0000142277.95052.94","article-title":"Aripiprazole and atypical neuroleptic malignant syndrome","volume":"43","author":"Spalding","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0155","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/01.WNF.0000240941.13876.5E","article-title":"Neuroleptic malignant syndrome from aripiprazole in an agitated pediatric patient","volume":"30","author":"Palakurthi","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.2515\/therapie\/2011012_bb0160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/01.chi.0000209786.29479.74","article-title":"Neuroleptic malignant syndrome and aripiprazole","volume":"45","author":"Hammerman","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0165","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/chi.0b013e31802ed925","article-title":"Acute dystonia associated with aripiprazole in a child","volume":"46","author":"Singh","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0170","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1345\/aph.1G331","article-title":"Acute dystonia with lowdosage aripiprazole in Tourette\u2019s disorder","volume":"40","author":"Fountoulakis","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.2515\/therapie\/2011012_bb0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1081\/CLT-53095","article-title":"Atypical experience: a case series of pediatric aripiprazole exposures","volume":"43","author":"Lofton","year":"2005","journal-title":"Clin Toxicol (Phila)"},{"key":"10.2515\/therapie\/2011012_bb0180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/PEC.0b013e318196faaf","article-title":"Prolonged toxicity in a 2-year-old after accidental ingestion of aripiprazole","volume":"25","author":"Melhem","year":"2009","journal-title":"Pediatr Emerg Care"},{"key":"10.2515\/therapie\/2011012_bb0185","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1542\/peds.2004-1268","article-title":"Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole","volume":"114","author":"Schonberger","year":"2004","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2011012_bb0190","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1081\/CLT-53097","article-title":"Aripiprazole (abilify) overdose in a child","volume":"43","author":"Seifert","year":"2005","journal-title":"Clin Toxicol (Phila)"},{"key":"10.2515\/therapie\/2011012_bb0195","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A multiple-center, randomized, doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0200","doi-asserted-by":"crossref","first-page":"s96","DOI":"10.1192\/bjp.191.51.s96","article-title":"Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study","volume":"51","author":"Woods","year":"2007","journal-title":"Br J Psychiatry Suppl"},{"key":"10.2515\/therapie\/2011012_bb0205","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0029-1202266","article-title":"Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review","volume":"42","author":"Bachmann","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.2515\/therapie\/2011012_bb0210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/cap.2008.0163","article-title":"Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data","volume":"20","author":"Robb","year":"2010","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0215","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1089\/cap.2004.14.505","article-title":"Aripiprazole in the treatment of bipolar disorder in children and adolescents","volume":"14","author":"Durkin","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0220","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","article-title":"Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study","volume":"70","author":"Findling","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/cap.2004.14.593","article-title":"The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review","volume":"14","author":"Barzman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0230","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1017\/S1092852900021519","article-title":"An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder","volume":"12","author":"Biederman","year":"2007","journal-title":"CNS Spectr"},{"key":"10.2515\/therapie\/2011012_bb0235","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1017\/S1092852900015443","article-title":"Aripiprazole in juvenile bipolar disorder comorbid with attention-deficit\/hyperactivity disorder: an open clinical trial","volume":"12","author":"Tramontina","year":"2007","journal-title":"CNS Spectr"},{"key":"10.2515\/therapie\/2011012_bb0240","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/cap.2009.0037","article-title":"Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit\/hyperactivity disorder: a randomized crossover trial","volume":"19","author":"Zeni","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0245","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.798","article-title":"A case series of patients with Tourette\u2019s syndrome in the United Kingdom treated with aripiprazole","volume":"21","author":"Davies","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0250","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4088\/JCP.v68n0717","article-title":"An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders","volume":"68","author":"Yoo","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0255","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/cap.2007.0064","article-title":"Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder","volume":"18","author":"Seo","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0260","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1089\/cap.2007.061","article-title":"Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts","volume":"18","author":"Budman","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0265","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1089\/cap.2009.0035","article-title":"Aripiprazole in children and adolescents with Tourette\u2019s disorder: an open-label safety and tolerability study","volume":"19","author":"Lyon","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0270","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/cap.2008.0149","article-title":"Open label aripiprazole in the treatment of youth with tic disorders","volume":"19","author":"Murphy","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","article-title":"Aripiprazole for maladaptive behavior in pervasive developmental disorders","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0280","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/cap.2008.093","article-title":"Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger\u2019s disorder: a 14-week, prospective, open-label study","volume":"19","author":"Stigler","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0285","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00023210-200923060-00005","article-title":"Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study","volume":"23","author":"Masi","year":"2009","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie\/2011012_bb0290","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/cap.2006.16.549","article-title":"Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities","volume":"16","author":"Valicenti-McDermott","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0295","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie\/2011012_bb0300","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"key":"10.2515\/therapie\/2011012_bb0305","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1089\/cap.2007.0124","article-title":"Aripiprazole in children with attention-deficit\/hyperactivity disorder","volume":"18","author":"Findling","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1089\/cap.2008.0111","article-title":"An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder","volume":"19","author":"Findling","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie\/2011012_bb0315","unstructured":"http:\/\/www.afssaps.fr\/Infos-de-securite\/Mises-au-point."},{"key":"10.2515\/therapie\/2011012_bb0320","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1345\/aph.1M643","article-title":"Anticholinergic use in children and adolescents after initiation of antipsychotic therapy","volume":"44","author":"Hong","year":"2010","journal-title":"Ann Pharmacother"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T03:43:15Z","timestamp":1554262995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0040595716307478"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011012","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}